Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Kimberley Driver

1PUBLICATIONS

15CO-AUTHORS

Fluid-structure interaction and aeroacoustics

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (1)

Sort by Publication Date:

|May 30, 2025

Effect of elexacaftor/tezacaftor/ivacaftor on systemic inflammation in cystic fibrosis.

Rosemary E Maher, Urszula M Cytlak-Chaudhuri, Saad Aleem

Pageof 1

Frequent Collaborators

1 joint publications

Urszula M Cytlak-Chaudhuri

1 joint publications

Saad Aleem

1 joint publications

Peter Barry

1 joint publications

Daniel Paul Brice

1 joint publications

Eva Caamaño Gutiérrez

1 joint publications

Edward Emmott

1 joint publications

Alexander Rothwell

1 joint publications

Emily Smith

1 joint publications

Mark Travis

1 joint publications

Dave Lee

Frequent Collaborators

1 joint publications

Urszula M Cytlak-Chaudhuri

1 joint publications

Saad Aleem

1 joint publications

Peter Barry

1 joint publications

Daniel Paul Brice

Top Related Videos

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on : Oct 15, 2017

See more related videos

Top Related Videos

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on : Oct 15, 2017

See more related videos